MADISON, Wis., Aug. 24, 2017 /PRNewswire/ -- Propeller
Health, a leading digital solution for respiratory medicine, today announced the expansion of its 2015 collaboration with GSK,
enabling both companies to prepare for and undertake commercial activities using the Propeller clip-on sensor and software
platform for use with GSK's ELLIPTA Inhaler. The companies will continue ongoing research and development efforts to collect
evidence from the Propeller clip-on sensor and software platform used in conjunction with GSK's respiratory medicines for asthma
and COPD.
The announcement follows successful CE marking and US FDA 510(k) class II clearance of the Propeller sensor and software
program for the ELLIPTA Inhaler, in late 2016. The clip-on sensor for the ELLIPTA Inhaler automatically records medication use,
which the Propeller platform analyzes and presents to patients and physicians through its data-driven digital interfaces,
providing an in-depth view into adherence.
"We are excited to be working closely with GSK to make the sensor for the ELLIPTA inhaler available in our commercial
programs, and for the first time, as part of commercial pilots with GSK outside the US," said David Van
Sickle, CEO and co-founder of Propeller. "Companion digital experiences simplify and personalize the management of chronic
respiratory disease, and help ensure individuals and their physicians realize the benefits of inhaled medicines."
Eric Dube, Senior Vice President and Head, Global Respiratory Franchise GSK, said: "Digital
innovations, like sensor technologies, will help us ensure patients receive the best possible package of care management and
treatment for their respiratory condition. We are excited to expand our collaboration with Propeller as a further step in our
journey towards achieving connected health systems for people with asthma and COPD."
The Propeller platform has been used by patients and physicians in over 55 commercial programs across the United States, including major healthcare systems, payers, employers and other commercial partners. It
is compatible with the majority of commonly used asthma and COPD inhaler devices including controller and reliever metered dose
inhalers (MDIs), and other inhaler devices (dry powder inhalers (DPIs) and soft mist inhalers (SMIs)).
GSK has been a leader in respiratory for over 45 years, developing new and first-in-class medicines, approaches and insights
which have helped to influence and support the management of asthma and chronic obstructive pulmonary disease (COPD). The
ELLIPTA inhaler is a platform inhaler device that is being used by GSK in the development of a range of innovative medicines
across its clinical development portfolio for respiratory diseases.
About Propeller
Propeller empowers people with asthma and COPD to live measurably better lives. In 2010 Propeller set out to modernize
respiratory medicine, enable people to minimize the impact of asthma and COPD on their daily lives, and connect them to their
physicians, environment and community. Propeller's information-powered approach to respiratory management guides physicians and
patients to the optimal path of therapy for each individual. With connected inhalers, digital interfaces, and personalized
insights, participants receive personal guidance and expert direction anytime. Backed by 3M Ventures (NYSE: MMM), SR One, Hikma
Ventures (LON: HIK), Safeguard Scientifics (NYSE: SFE), Social Capital and other investors, Propeller received the American
Telemedicine Association's 2016 President's Award for Innovation in Remote Healthcare and was recognized as one of the top
"Fierce 15" medical device companies in 2015 by FierceMedicalDevices. In 2017, Fast Company named Propeller as one of the most
innovative companies in Health. For more information visit: www.propellerhealth.com
View original content:http://www.prnewswire.com/news-releases/propeller-health-announces-expansion-of-digital-health-collaboration-with-glaxosmithkline-to-improve-management-of-asthma-and-copd-300508991.html
SOURCE Propeller Health